Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy

Bibliography

• STEIN H, MASON DY, GERDES et al: The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood (1985) 66:848–858.
   PubMed Web of Science ®Google Scholar
• KADIN ME: Anaplastic large cell lymphoma and its morphological variants. Cancer Surv. (1997) 30:77–86.
   PubMedGoogle Scholar
• MORRIS SW, KIRSTEIN MN, VALENTINE MB et al: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non- Hodgkin's lymphoma [published erratum appears in Science 1995 Jan 20;267(5196):316-317]. Science (1994) 263:1281–1284.
   PubMed Web of Science ®Google Scholar
• SHIOTA M, FUJIMOTO J, SEMBA T, SATOH H, YAMAMOTO T, MORI S: Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene (1994) 9:1567–1574.
   PubMed Web of Science ®Google Scholar
• CHAN, JK: Anaplastic large cell lymphoma: redefining its morphologic spectrum and importance of recognition of the ALK-positive subset. Adv. Anat. Pathol (1998) 5:281–313.
   PubMedGoogle Scholar
• BENHARROCH D, MEGUERIAN-BEDOYAN Z, LAMANT L et al.: ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood (1998) 91:2076–2084.
   PubMed Web of Science ®Google Scholar
• KINNEY MC, AND KADIN, ME: The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation. Am. J. Clin. Pathol (1999) 111:S56–S67.
   PubMed Web of Science ®Google Scholar
• SKINNIDER BF, CONNORS JM, SUTCLIFFE SB, GASCOYNE RID: Anaplastic large cell lymphoma: a clinicopathologic analysis. Hematol Oncol (1999) 17:137–148.
   PubMed Web of Science ®Google Scholar
• JAFFE ES: Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod. Pathol (2001) 14:219–228.
   PubMed Web of Science ®Google Scholar
• SANDER CA, FLAIG MJ, JAFFE ES: Cutaneous manifestations of lymphoma: a clinical guide based on the WHO classification. World Health Organization. Clin Lymphoma (2001) 2:86-100; discussion 101–102.
   Google Scholar
• PULFORD K, LAMANT L, MORRIS SW et al: Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1.Blood (1997) 89:1394–1404.
   PubMed Web of Science ®Google Scholar
• JAFFE ES: Mature T-cell and NK-cell lymphomas in the pediatric age group. Am. J. Clin. Pathol. (2004) 122(Suppi.):S110–S121.
   Google Scholar
• DREXLER HG, GIGNAC SM, VON WASIELEWSKI R, WERNER M, DIRKS WG: Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia (2000) 14:1533–1559.
   PubMed Web of Science ®Google Scholar
• STEIN H, FOSS HD, DURKOP H et al: CD30(÷) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood (2000) 96:3681–3695.
   PubMed Web of Science ®Google Scholar
• •This review gives a comprehensive description of both the molecular pathogenesis and the clinical features of ALK-positive ALCLs.
   Google Scholar
• FALINI B, PILERI S, ZINZANI PL et al: ALK+ lymphoma: clinico-pathological findings and outcome. Blood (1999) 93:2697–2706.
   PubMed Web of Science ®Google Scholar
• GASCOYNE RD, AOUN P, WU D et al: Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood (1999) 93:3913–3921.
   PubMed Web of Science ®Google Scholar
• BRUGIERES L, DELEY MC, PACQUEMENT H et al: CD30(-F) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood (1998) 92:3591–3598.
   PubMed Web of Science ®Google Scholar
• MASSIMINO M, SPREAFICO F, LUKSCH R, GIARDINI R: Prognostic significance of p80 and visceral involvement in childhood CD30 anaplastic large cell lymphoma (ALCD. Med. Pediatr. Oncol (2001) 37:97–102.
   PubMedGoogle Scholar
• SAVAGE KJ, CHHANABHAI M, GASCOYNE RD, CONNORS JM: Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann. Oncol (2004) 15:1467–1475.
   PubMed Web of Science ®Google Scholar
• WILLIAMS DM, HOBSON R, IMESON J, GERRARD M, MCCARTHY K, PINKERTON CR: Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens. Br. Haematol (2002) 117:812–820.
   PubMed Web of Science ®Google Scholar
• BRUGIERES L, QUARTIER P, LE DELEY MC et al: Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children-a report from the French Society of Pediatric Oncology. Ann. Oncol (2000) 11:53–58.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG G, SZALLASI A, BIEGEL JA et al.: Early molecular detection of central nervous system relapse in a child with systemic anaplastic large cell lymphoma: Case report and review of the literature. Pediatr. Blood Cancer (2005) 44:400–406.
   PubMedGoogle Scholar
• ADAM P, KATZENBERGER T, SEEBERGER H et al: A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2,5) (p23;q35) chromosome translocation. Am. J. Sorg. Pathol (2003) 27:1473–1476.
   PubMed Web of Science ®Google Scholar
• CHIKATSU N, KOJIMA H, SUZUKAWA K et al: ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC). Mod Pathol (2003) 16:828–832.
   PubMed Web of Science ®Google Scholar
• DE PAEPE P, BAENS M, VAN KRIEKEN H et al: ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood (2003) 102:2638–2641.
   PubMed Web of Science ®Google Scholar
• GAS COYNE RD, LAMANT L, MARTIN-SUBERO JI et al.: ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood(2003) 102:2568–2573.
   PubMedGoogle Scholar
• ONCIU M, BEHM FG, DOWNING JR et al.: ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood(2003) 102:2642–2644.
   PubMed Web of Science ®Google Scholar
• MCMANUS DT, CATHERWOOD MA, CAREY PD, CUTHBERT RJ, ALEXANDER HD: ALK-positive diffuse large B-cell lymphoma of the stomach associated with a clathrin-ALK rearrangement. Hum. Pathol (2004) 35:1285–1288.
   PubMed Web of Science ®Google Scholar
• DELSOL G, LAMANT L, MARIAME B et al.: A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood (1997) 89:1483–1490.
   PubMed Web of Science ®Google Scholar
• IWAHARA T, FUJIMOTO J, WEN D et al.: Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene (1997) 14:439–449.
   PubMed Web of Science ®Google Scholar
• MORRIS SW, NAEVE C, MATHEW P et al: ALK, the chromosome 2 gene locus altered by the t(2,5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) [published erratum appears in Oncogene 1997 Dec 4; 15 (23) :2883]. Oncogene (1997) 14:2175–2188.
   PubMed Web of Science ®Google Scholar
• •This is the first description of ALK as a receptor tyrosine kinase expressed in the developing brain.
   Google Scholar
• LOREN CE, SCULLY A, GRABBE C et al.: Identification and characterization of DAlk: a novel Drosophila melanogaster RTK which drives ERK activation in vivo. Genes Cells (2001) 6:531–544.
   PubMedGoogle Scholar
• BOWDEN ET, STOICA GE, WELLSTEIN A: Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. ./. Biol. Chem. (2002) 277:35862–35868.
   PubMedGoogle Scholar
• STOICA GE, KUO A, POWERS C et al: Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. ./. Biol. Chem. (2002) 277:35990–35998.
   PubMed Web of Science ®Google Scholar
• STOICA GE, KUO A, AIGNER A et al: Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J. Biol. Chem. (2001) 276:16772–16779.
   PubMed Web of Science ®Google Scholar
• POWERS C, AIGNER A, STOICA GE, MCDONNELL K, WELLSTEIN A: Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. ./. Biol. Chem. (2002) 277:14153–14158.
   PubMed Web of Science ®Google Scholar
• LAMANT L, DASTUGUE N, PULFORD K, DELSOL G, MARIAME B: A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2) (q25;p23) translocation. Blood (1999) 93:3088–3095.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ L, PINYOL M, HERNANDEZ S et al: TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood (1999) 94:3265–3268.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ L, BEA S, BELLOSILLO B et al: Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. Am. J. Pathol (2002) 160:1487–1494.
   PubMed Web of Science ®Google Scholar
• ROSENWALD A, OTT G, PULFORD K et al: t(1;2)(q21;p23) and t(2;3)(p23;q21): two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma. Blood (1999) 94:362–364.
   PubMed Web of Science ®Google Scholar
• COLLEONI GW, BRIDGE JA, GARICOCHEA B, LIU J, FILIPPA DA, LADANYI M: ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am. J. Pathol (2000) 156:781–789.
   PubMed Web of Science ®Google Scholar
• TRINEI M, LANFRANCONE L, CAMPO E et al: A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res. (2000) 60:793–798.
   PubMed Web of Science ®Google Scholar
• MA Z, COOLS J, MARYNEN P et al.: Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood (2000) 95:2144–2149.
   PubMed Web of Science ®Google Scholar
• LIANG X, MEECH SJ, ODOM LF et al: Assessment of t(2,5) (p23;q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphoma. Am. I Clin. Pathol (2004) 121:496–506.
   PubMed Web of Science ®Google Scholar
• TOURIOL C, GREENLAND C, LAMANT L et al.: Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood (2000) 95:3204–3207.
   PubMed Web of Science ®Google Scholar
• TORT F, PINYOL M, PULFORD K et al: Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab. Invest. (2001) 81:419–426.
   PubMed Web of Science ®Google Scholar
• TORT F, CAMPO E, POHLMAN B, HSI E: Heterogeneity of genomic breakpoints in MSN-ALK translocations in anaplastic large cell lymphoma. Hum. Pathol (2004) 35:1038–1041.
   PubMed Web of Science ®Google Scholar
• COOLS J, WLODARSKA I, SOMERS R et al.: Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer (2002) 34:354–362.
   PubMed Web of Science ®Google Scholar
• DUYSTER J, BAI RY, MORRIS SW: Translocations involving anaplastic lymphoma kinase (ALK). Oncogene (2001) 20:5623–5637.
   PubMed Web of Science ®Google Scholar
• CHIARLE R, GONG JZ, GUASPARRI I et al: NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood (2003) 101:1919–1927.
   PubMed Web of Science ®Google Scholar
• ••This paper described for the firsttime an ALCL-like tumour in NPM/ALK transgenic mice, providing a suitable animal model for in vivo testing of ALK-targeted therapies.
   Google Scholar
• ZAMO A, CHIARLE R, PIVA R et al: Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene (2002) 21:1038–1047.
   PubMed Web of Science ®Google Scholar
• FUJIMOTO J, SHIOTA M, IWAHARA T et al.: Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2:5). Proc. Natl. Acad. Sci. USA (1996) 93:4181–4186.
   PubMed Web of Science ®Google Scholar
• BISCHOF D, PULFORD K, MASON DY, & MORRIS SW: Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma- associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol. Cell. Biol. (1997) 17:2312–2325.
   PubMed Web of Science ®Google Scholar
• •The paper reports the identification of essential functional NPM/ALK protein domains required for transformation in vitro.
   Google Scholar
• MASON DY, PULFORD KA, BISCHOF D et al: Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation. Cancer Res. (1998) 58:1057–1062.
   PubMed Web of Science ®Google Scholar
• BAT RY, DIETER P, PESCHEL C, MORRIS SW, DUYSTER J: Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol. Cell. Biol. (1998) 18:6951–6961.
   PubMedGoogle Scholar
• ERGIN M, DENNING MF, IZBAN KF et al.: Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein. Exp. Hematol. (2001) 29:1082–1090.
   PubMed Web of Science ®Google Scholar
• TURTURRO F, ARNOLD MD, FRIST AY, PULFORD K: Model of inhibition of the NPM-ALK kinase activity by herbimycin A. Clin. Cancer Res. (2002) 8:240–245.
   PubMed Web of Science ®Google Scholar
• BAT RY, OUYANG T, MIETHING C, MORRIS SW, PESCHEL C, DUYSTER J: Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood (2000) 96:4319–4327.
   PubMedGoogle Scholar
• NIEBOROWSKA-SKORSKA M, SLUPIANEK A, XUE L et al: Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res. (2001) 61:6517–6523.
   PubMed Web of Science ®Google Scholar
• SLUPIANEK A, NIEBOROWSKA-SKORSKA M, HOSER G et al: Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. (2001) 61:2194–2199.
   PubMed Web of Science ®Google Scholar
• ZHANG Q, RAGHUNATH PN, XUE L et al: Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. Immunol. (2002) 168:466–474.
   Google Scholar
• KUEFER MU, LOOK AT, PULFORD K et al: Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood (1997) 90:2901–2910.
   PubMed Web of Science ®Google Scholar
• LANGE K, UCKERT W, BLANKENSTEIN T et al: Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Oncogene (2003) 22:517–527.
   PubMed Web of Science ®Google Scholar
• MIETHING C, GRUNDLER R, FEND F et al: The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model. Oncogene (2003) 22:4642–4647.
   PubMed Web of Science ®Google Scholar
• SCHENDEL DJ, GANSBACHER B: Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment. Cancer Res. (1993) 53:4020–4025.
   PubMedGoogle Scholar
• SHILYANSKY J, NISHIMURA MI, YANNELLI JR et al.: T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. Proc. Nati Acad. Sci. USA (1994) 91:2829–2833.
   PubMed Web of Science ®Google Scholar
• KAWAKAMI Y, DANG N, WANG X et al: Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. Inonunother. (2000) 23:17–27.
   PubMed Web of Science ®Google Scholar
• KAWAKAMI Y, & ROSENBERG SA: Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int. Rev Immunol. (1997) 14:173–192.
   PubMedGoogle Scholar
• OVERWIJK WW, THEORET MR, FINKELSTEIN S et al: Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. Exp. Med. (2003) 198:569–580.
   PubMed Web of Science ®Google Scholar
• ZHANG L, CONEJO-GARCIA JR, KATSAROS D et al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl. I Med. (2003) 348:203–213.
   PubMed Web of Science ®Google Scholar
• DAVE SS, WRIGHT G, TAN B et al: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. (2004) 351:2159–2169.
   PubMed Web of Science ®Google Scholar
• LENGAGNE R, LE GAL FA, GARCETTE M et al: Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8+ T cells. Cancer Res. (2004) 64:1496–1501.
   PubMed Web of Science ®Google Scholar
• BERZOFSKY JA, TERABE M, OH S et al: Progress on new vaccine strategies for the immunotherapy and prevention of cancer. Clin. Invest. (2004) 113:1515–1525.
   Google Scholar
• PANELLI MC, WANG E, MONSURRO V et al.: Vaccination with T cell-defined antigens. Expert Opin. Biol. Ther. (2004) 4:697–707.
   PubMedGoogle Scholar
• GILBOA E: The makings of a tumor rejection antigen. Immunity (1999) 11:263–270.
   PubMed Web of Science ®Google Scholar
• RENKVIST N, CASTELLI C, ROBBINS PF, PARMIANI G: A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. (2001) 50:3–15.
   PubMed Web of Science ®Google Scholar
• NOVELLINO L, CASTELLI C, PARMIANI G: A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. (2005) 54:187–207.
   PubMed Web of Science ®Google Scholar
• PASSONI L, SCARDINO A, BERTAZZOLI C et al.: ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood (2002) 99:2100–2106.
   Google Scholar
• •In this study, the first immunogenic ALK-derived peptides suitable for the design of anti-ALK cancer vaccine protocols were identified.
   Google Scholar
• DUNN GP, OLD LJ, SCHREIBER RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 21:137–148.
   PubMed Web of Science ®Google Scholar
• AMADO RG, MITSUYASU RT, SYMONDS G et al: A Phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum. Gene Ther. (1999) 10:2255–2270.
   PubMed Web of Science ®Google Scholar
• BRUMMELKAMP TR, BERNARDS R, AGAMI R: Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 2:243–247.
   PubMed Web of Science ®Google Scholar
• KASHANI-SABET M: Ribozyme therapeutics. I Investig. Dermatol Symp. Proc. (2002) 7:76–78.
   PubMed Web of Science ®Google Scholar
• AMADO RG, MITSUYASU RT, ROSENBLATT JD et al: Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a Phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum. Gene Ther. (2004) 15:251–262.
   PubMed Web of Science ®Google Scholar
• BOYD MP, NGOK FK, TODD AV, SYMONDS GP, MACPHERSON JL, AMADO RG: Critical steps in the implementation of hematopoietic progenitor-cell gene therapy using ribozyme vectors: a laboratory protocol. Methods Mol Biol. (2004) 252:599–616.
   PubMedGoogle Scholar
• SCHERER LJ, ROSSI JJ: Approaches for the sequence-specific knockdown of mRNA. Nat. Biotechnol (2003) 21:1457–1465.
   PubMed Web of Science ®Google Scholar
• SCHUBERT S, KURRECK J: Ribozyme-and deoxyribozyme-strategies for medical applications. Curr. Drug Targets (2004) 5:667–681.
   PubMed Web of Science ®Google Scholar
• BLOUNT KF, UHLENBECK OC: The hammerhead ribozyme. Biochem. Soc. Trans. (2002) 30:1119–1122.
   PubMed Web of Science ®Google Scholar
• HUBINGER G, WEHNES E, XUE L, MORRIS SW, MAURER U: Hammerhead ribozyme-mediated cleavage of the fusion transcript NPM-ALK associated with anaplastic large-cell lymphoma. Exp. Hematol (2003) 31:226–233.
   PubMed Web of Science ®Google Scholar
• RYTHER RC, FLYNT AS, PHILLIPS JA, 3rd, PATTON JG: siRNA therapeutics: big potential from small RNAs. Gene Ther. (2005) 12:5–11.
   PubMed Web of Science ®Google Scholar
• IZQUIERDO M: Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther. (2005) 12:217–227.
   PubMed Web of Science ®Google Scholar
• RITTER U, DAMM-WELK C, FUCHS U, BOHLE RM, BORKHARDT A, WOESSMANN W: Design and evaluation of chemically synthesized siRNA targeting the NPM-ALK fusion site in anaplastic large cell lymphoma (ALCD. Oligonucleotides (2003) 13:365–373.
   PubMed Web of Science ®Google Scholar
• FABBRO D, PARKINSON D, MATTER A: Protein tyrosine kinase inhibitors: new treatment modalities? Curl: Opin. Pharmacol (2002) 2:374–381.
   Google Scholar
• NOBLE ME, ENDICOTT JA, JOHNSON LN: Protein kinase inhibitors: insights into drug design from structure. Science (2004) 303:1800–1805.
   PubMed Web of Science ®Google Scholar
• PERRONE F, DI MAIO M, BUDILLON A, NORMANNO N: Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials. Curr. Opin. Oncol (2005) 17:123–129.
   PubMedGoogle Scholar
• DEININGER M, BUCHDUNGER E, DRUKER BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood (2005) (Epub ahed of print, Dec.23 2004).
   Google Scholar
• LYDON NB, DRUKER BJ: Lessons learned from the development of imatinib. Leuk. Res. (2004) 28\(Suppl. 1):529–538.
   Google Scholar
• DRUKER BJ: Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. (2004) 91:1–30.
   PubMed Web of Science ®Google Scholar
• SCHINDLER T, BORNMANN W, PELLICENA P, MILLER WT, CLARKSON B, KURIYAN J: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 289: 1938-1942.
   Google Scholar
• NAGAR B, BORNMANN WG, PELLICENA P et al.: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. (2002) 62:4236–4243.
   PubMed Web of Science ®Google Scholar
• HUBBARD SR: Protein tyrosine kinases: autoregulation and small-molecule inhibition. Curr. Opin. Struct. Biol. (2002) 12:735–741.
   PubMedGoogle Scholar
• FABBRO D, RUETZ S, BUCHDUNGER E et al: Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther. (2002) 93:79–98.
   PubMed Web of Science ®Google Scholar
• MANNING G, WHYTE DB, MARTINEZ R, HUNTER T, SUDARSANAM S: The protein kinase complement of the human genome. Science (2002) 298:1912–1934.
   PubMed Web of Science ®Google Scholar
• COWAN-JACOB SW, GUEZ V, FENDRICH G et al: Imatinib (5TI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med. Chem. (2004) 4:285–299.
   PubMed Web of Science ®Google Scholar
• GAMBACORTI-PASSERINI CB, GUNBY RH, PIAZZA R, GALIETTA A, ROSTAGNO R, SCAPOZZA L: Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol (2003) 4:75–85.
   PubMed Web of Science ®Google Scholar
• GUNBY RH, SOTTOCORNOLA R, GASSER M, SCAPOZZA L, GAMBACORTI-PASSERINI CB: Generation and Verification of a Three-Dimensional Model of the ALK Kinase Domain: ALK - a `Supermutane of Abl. Blood (2004) 104:952a.
   Google Scholar
• LA ROSEE P, CORBIN AS, STOFFREGEN EP, DEININGER MW, DRUKER BJ: Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, 5TI571). Cancer Res. (2002) 62:7149–7153.
   PubMed Web of Science ®Google Scholar
• WISNIEWSKI D, LAMBEK CL, LIU C et al: Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res. (2002) 62:4244–4255.
   PubMed Web of Science ®Google Scholar
• SHAH NP, TRAN C, LEE FY, CHEN P, NORRIS D, SAWYERS CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 305:399–401.
   PubMed Web of Science ®Google Scholar
• TOKARSKI JS, NEWITT J, LEE FY et al: The crystal structure of Abl Kinase with BMS-354825, a dual SRC/ABL kinase inhibitor. Blood (2004) 104:160a
   Google Scholar
• GUMIREDDY K, BAKER SJ, COSENZA SC et al: A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl. Acad. Li. USA (2005) 102:1992–1997.
   PubMed Web of Science ®Google Scholar
• GUNBY RH, GAMBACORTI-PASSERINI C, MOLOGNI L et al: Anaplastic Lymphoma kinase assay, reagents and composition thereof. In Patent No. 03005186.6, (2003) Filed 07.03.03, Italy.
   Google Scholar
• OMURA S, IWAI Y, HIRANO A et al: A new alkaloid AM-2282 OF Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. J. Arabia. (Tokyo) (1977) 30:275–282.
   Google Scholar
• PRADE L, ENGH RA, GIROD A, KINZEL V, HUBER R, BOSSEMEYER D: Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Structure (1997) 5:1627–1637.
   PubMed Web of Science ®Google Scholar
• GUNBY RH, TARTARI CJ, DONELLA-DEANA A, PORCHIA F, SCAPOZZA L, GAMBACORTI-PASSERINI C: Enzyme-Linked Immunosorbent Assay for screening inhibitors of the oncogenic Anaplastic Lymphoma Kinase. The Hematol 1 (2005) In press.
   Google Scholar
• GESCHER A: Analogs of staurosporine: potential anticancer drugs? an. Pharmacol (1998) 31:721–728.
   Google Scholar
• TAKAHASHI I, SAITOH Y, YOSHIDA M et al: UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. Antibiot. ( Tokyo) (1989) 42:571–576.
   Google Scholar
• GRAVES PR, YU L, SCHWARZ JK et al: The Chkl protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01.J. Biol. Chem. (2000) 275:5600–5605.
   PubMed Web of Science ®Google Scholar
• SENDEROWICZ AM, SAUSVILLE EA: Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. (2000) 92:376–387.
   PubMed Web of Science ®Google Scholar
• SAUSVILLE EA, ARBUCK SG, MESSMANN R et al.: Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. Clin. Oncol. (2001) 19:2319–2333.
   Google Scholar
• CHENG M, WAN W, ALBOM M et al: Identification and characterisation of an ALK inhibitor that attenuates the proliferation and survival of anaplastic large cell lymphoma-derived cell lines and ALK dependent cell lines. Blood (2004) 104:681a
   Google Scholar
• HORWELL DC: The Peptoid' approach to the design of non-peptide, small molecule agonists and antagonists of neuropeptides. Trends Biotech. (1995) 13:132–134.
   PubMedGoogle Scholar
• COCHRAN AG: Antagonists of protein-protein interactions. Chem. Biol. (2000) 7:R85–R94.
   Google Scholar
• WANG JL, LIU D, ZHANG ZJ et al: Structure-based discovery of an organic compound that binds Bc1-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sri. USA (2000) 97:7124–7129.
   PubMed Web of Science ®Google Scholar
• LICKLITER JD, WOOD NJ, JOHNSON L et al.: HA14-1 selectively induces apoptosis in Bc1-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death. Leukemia (2003) 17:2074–2080.
   PubMed Web of Science ®Google Scholar
• PEI XY, DAI Y, GRANTS: The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bc1-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia (2003) 17:2036–2045.
   PubMed Web of Science ®Google Scholar
• PEI XY, DAI Y, GRANTS: The small-molecule Bc1-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. Mol Cancer Ther. (2004) 3:1513–1524.
   PubMed Web of Science ®Google Scholar
• VASSILEV LT, VU BT, GRAVES B et al: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.Science (2004) 303:844–848.
   PubMed Web of Science ®Google Scholar
• KLEIN C, VASSILEV LT: Targeting the p53-MDM2 interaction to treat cancer. Br. J. Cancer (2004) 91:1415–1419.
   PubMed Web of Science ®Google Scholar
• BOGAN AA, THORN KS: Anatomy of hot spots in protein interfaces. J. Mo/. (1998) 280:1–9.
   PubMed Web of Science ®Google Scholar
• CLACKSON T, WELLS JA: A hot spot of binding energy in a hormone-receptor interface. Science (1995) 267:383–386.
   PubMed Web of Science ®Google Scholar
• GADEK TR, NICHOLAS JB: Small molecule antagonists of proteins. Biochem. Pharmacol (2003) 65:1–8.
   PubMed Web of Science ®Google Scholar
• CROCKETT DK, UN Z, ELENITOBA-JOHNSON KS, LIM MS: Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene (2004) 23:2617–2629.
   PubMed Web of Science ®Google Scholar
• •This is the first large scale proteomic analysis of NPM/ALK + ALCL cell lines. A total of 57 interacting proteins were identified as proximal NPM/ALK interactors.
   Google Scholar
• NECKERS L: Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. Curr. Med. Chem. (2003) 10:733–739.
   PubMed Web of Science ®Google Scholar
• XU W, MIMNAUGH EG, KIM JS, TREPEL JB, NECKERS LM: Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2.Cell Stress Chaperones (2002) 7:91–96.
   Google Scholar
• NIMMANAPALLI R, O'BRYAN E, BHALLA K: Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. (2001) 61:1799–1804.
   PubMed Web of Science ®Google Scholar
• BASSO AD, SOLIT DB, CHIOSIS G, GIRT B, TSICHLIS P, ROSEN N: Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. Biol. Chem. (2002) 277:39858–39866.
   Web of Science ®Google Scholar
• GOETZ MP, TOFT DO, AMES MM, ERLICHMAN C: The Hsp90 chaperone complex as a novel target for cancer therapy. Ann. Oncol (2003)14:1169–1176.
   PubMed Web of Science ®Google Scholar
• GRENERT JP, SULLIVAN WP, FADDEN P et al.: The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. Biol. Chem. (1997) 272:23843–23850.
   Web of Science ®Google Scholar
• PRODROMOU C, ROE SM, O'BRIEN R, LADBURY JE, PIPER PW, PEARL LH: Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell (1997) 90:65–75.
   PubMed Web of Science ®Google Scholar
• STEBBINS CE, RUSSO AA, SCHNEIDER C, ROSEN N, HARTL FU, & PAVLETICH NP: Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell (1997) 89:239–250.
   PubMed Web of Science ®Google Scholar
• BELIAKOFF J, WHITESELL L: Hsp90: an emerging target for breast cancer therapy. Anticancer Drugs (2004) 15:651–662.
   PubMed Web of Science ®Google Scholar
• SOLIT DB, SCHER HI, ROSEN N: Hsp90 as a therapeutic target in prostate cancer. Semia Oncol (2003) 30:709–716.
   PubMed Web of Science ®Google Scholar
• GORRE ME, ELLWOOD-YEN K, CHIOSIS G, ROSEN N, SAWYERS CL: BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.Blood (2002) 100:3041–3044.
   PubMed Web of Science ®Google Scholar
• RAHMANI M, REESE E, DAI Y et al: Co-treatment with SAHA and 17-AAG synergistically induces apoptosis in Bcr-Abl+ cells sensitive and resistant to STI-571 in association with down-regulation of Bcr-Abl, abrogation of STAT5 activity, and Bax conformational change. Mol Pharmacol. (2005) (Epub ahed of print, Dec.29 2004)
   Google Scholar
• MINAMI Y, KIYOI H, YAMAMOTO Y et al.: Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia (2002) 16:1535–1540.
   PubMed Web of Science ®Google Scholar
• BONVINI P, GASTALDI T, FALINI B, ROSOLEN A: Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17- allylamino, 17-demethoxygeldanamycin. Cancer Res. (2002) 62:1559–1566.
   PubMed Web of Science ®Google Scholar
• •This study indicates the potential clinical application of Hsp90 inhibitors in the treatment of ALK-positive ALCL.
   Google Scholar
• DRUKER BJ: Overcoming resistance to imatinib by combining targeted agents. Mol. Cancer Ther. (2003) 2:225–226.
   PubMedGoogle Scholar
• CUSSAC D, GREENLAND C, ROCHE S et al.: Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood (2004) 103:1464–1471.
   PubMed Web of Science ®Google Scholar
• SCHULTZ RM, MERRIMAN RL, ANDIS SL et al.: LI vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anti-Cancer Res. (1995) 15:1135–1139.
   PubMed Web of Science ®Google Scholar
• POWIS G, BONJOUKLIAN R, BERGGREN MM et al.: Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res. (1994) 54:2419–2423.
   PubMed Web of Science ®Google Scholar
• SANCHEZ-MARGALET V, GOLDFINE ID, VLAHOS CJ, SUNG CK: Role of phosphatidylinositol-3-kinase in insulin receptor signaling: studies with inhibitor, LY294002.Biochem. Biophys. Res. Commun. (1994) 204:446–452.
   PubMedGoogle Scholar
• SEMBA S, ITOH N, ITO M et al.: Down-regulation of PIK3CG, a catalytic subunit of phosphatidylinositol 3-0H kinase, by CpG hypermethylation in human colorectal carcinoma. Clin. Cancer Res. (2002) 8:3824–3831.
   PubMed Web of Science ®Google Scholar
• RONG SB, HU Y, ENYEDY I et al.: Molecular modeling studies of the Akt PH domain and its interaction with phosphoinositides. J. Med. Chem. (2001) 44:898–908.
   PubMed Web of Science ®Google Scholar
• WEST KA, CASTILLO SS, DENNIS, PA Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat. (2002) 5: 234–248.
   PubMed Web of Science ®Google Scholar
• BRAUN-DULLAEUS RC, MANN MJ, SEAY U et al.: Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler. Thromb. Vasc. Biol. (2001) 21:1152–1158.
   PubMed Web of Science ®Google Scholar
• SLUPIANEK A, SKORSKI T: NPM/ALK downregulates p27Kipl in a PI-3K-dependent manner. Exp. Hematol. (2004) 32:1265–1271.
   PubMed Web of Science ®Google Scholar
• RASSIDAKIS GZ, FERETZAKI M, ATWELL C et al.: Inhibition of Akt increases p27Kipl levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood (2005) 105:827–829.
   PubMed Web of Science ®Google Scholar
• HUANG S, HOUGHTON PJ: Mechanisms of resistance to rapamycins. Drug Resist. Updat. (2001) 4:378–391.
   PubMed Web of Science ®Google Scholar
• NESHAT MS, MELLINGHOFF IK, TRAN C et al.: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Nati Acad. Li. USA (2001) 98:10314–10319.
   PubMed Web of Science ®Google Scholar
• AMIN HM, MEDEIROS LJ, MAY et al: Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene (2003) 22:5399–5407.
   PubMed Web of Science ®Google Scholar
• RUCHATZ H, COLUCCIA AM, STANO P, MARCHESI E, GAMBACORTI-PASSERINI C: Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. Exp. Hematol. (2003) 31:309–315.
   PubMed Web of Science ®Google Scholar
• MEYDAN N, GRUNBERGER T, DADI H et al.: Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature (1996) 379:645–648.
   PubMed Web of Science ®Google Scholar
• SUDBECK EA, LIU XP, NARLA RK et al.: Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin. Cancer Res. (1999) 5:1569–1582.
   PubMed Web of Science ®Google Scholar
• TURKSON J, JOVE R: STAT proteins: novel molecular targets for cancer drug discovery. Oncogene (2000) 19:6613–6626.
   PubMed Web of Science ®Google Scholar
• KERR IM, COSTA-PEREIRA AP, LILLEMEIER BE STROBL B: Of JAKs, STATs, blind watchmakers, jeeps and trains. FEBS Lett. (2003) 546:1–5.
   PubMedGoogle Scholar
• TURKSON J, RYAN D, KIM JS et al.: Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. (2001) 276:45443–45455.
   PubMed Web of Science ®Google Scholar
• EPLING-BURNETTE PK, LIU JH, CATLETT-FALCONE R et al.: Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. (2001) 107:351–362.
   PubMed Web of Science ®Google Scholar
• COLUCCIA AM, PEREGO S, CLERIS L et al.: Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo. Blood (2004) 103:2787–2794.
   PubMed Web of Science ®Google Scholar
• SLUPIANEK A, HOSER G, MAJSTEREK I et al.: Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol. Cell. Biol. (2002) 22:4189–4201.
   PubMed Web of Science ®Google Scholar
• GAUTSCHI 0, TSCHOPP S, OLIE RA et al.: Activity of a novel bc1-2/bc1-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J. Nati Cancer Inst. (2001) 93:463–471.
   Google Scholar
• MARCUCCI G, BYRD JC, DAI G et al.: Phase I and pharmacodynamic studies of G3139, a Bc1-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood (2003) 101:425–432.
   PubMed Web of Science ®Google Scholar
• SHANGARY S, JOHNSON DE: Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bc1-2 protein family. Leukemia (2003) 17:1470–1481.
   PubMedGoogle Scholar
• TZUNG SP, KIM KM, BASANEZ G et al.: Antimycin A mimics a cell-death-inducing Bc1-2 homology domain 3.Nat. Cell Biol. (2001) 3:183–191.
   Google Scholar
• CHAN SL, LEE MC, TAN KO et al.: Identification of chelerythrine as an inhibitor of Bc1XL function../. Biol. Chem. (2003) 278:20453–20456.
   Google Scholar
• ENYEDY IJ, LING Y, NACRO K et al.: Discovery of small-molecule inhibitors of Bc1-2 through structure-based computer screening. J. Med. Chem. (2001) 44:4313–4324.
   PubMed Web of Science ®Google Scholar
• WALENSKY LD, KUNG AL, ESCHER I et al.: Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science (2004) 305:1466–1470.
   PubMed Web of Science ®Google Scholar
• •This paper describes an in vivo inhibitor of the BH3 domain of Bc12-family members including Bc1XL known as an essential mediator of NPM/ALK survival potential.
   Google Scholar
• HUBINGER G, SCHEFFRAHN I, MULLER E et al.: The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation. Exp. Hematol (1999) 27:1796–1805.
   PubMedGoogle Scholar
• NISHIKORI M, MAESAKO Y, UEDA C, KURATA M, UCHIYAMA T, OHNO H: High-level expression of BCL3 differentiates t(2;5) (1)23; q35)-positive anaplastic large cell lymphoma from Hodgkin disease. Blood (2003) 101:2789–2796.
   PubMed Web of Science ®Google Scholar
• RASSIDAKIS GZ, OYARZO MP, MEDEIROS, LJ: BCL-3 overexpression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Blood (2003) 102:1146–1147.
   PubMedGoogle Scholar
• HORIE R, WATANABE M, ISHIDA T, KOIWA T et al.: The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma. Cancer Cell (2004) 5:353–364.
   PubMed Web of Science ®Google Scholar
• GRUSS HJ, BOIANI N, WILLIAMS DE, ARMITAGE RJ, SMITH CA, GOODWIN RG: Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood (1994) 83:2045–2056.
   PubMed Web of Science ®Google Scholar
• FRANKE AC, JUNG D, ELLIS TM: Characterization of the CD3OL binding domain on the human CD30 molecule using anti-CD30 antibodies. Hybridoma (2000) 19:43–48.
   PubMedGoogle Scholar
• TIAN ZG, LONGO DL, FUNAKOSHI S et al.: In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res. (1995) 55:5335–5341.
   PubMed Web of Science ®Google Scholar
• PFEIFER W, LEVI E, PETROGIANNIS-HALIOTIS T, LEHMANN L, WANG Z, KADIN ME: A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1). Am. Pathol (1999) 155:1353–1359.
   Google Scholar
• •The authors propose the use of an anti-CD30 antibody able to suppress growth and viability of ALK-positive ALCL cells as a potential clinical strategy.
   Google Scholar
• PASQUALUCCI L, WASIK M, TEICHER BA et al.: Antitumor activity of anti-CD30 immunotoxin (Ber-H2/ saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. Blood (1995) 85:2139–2146.
   PubMed Web of Science ®Google Scholar
• MORA J, FILIPPA DA, THALER HT, POLYAK T, CRANOR ML, WOLLNER N: Large cell non-Hodgkin lymphoma of childhood: Analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer Center. Cancer (2000) 88:186–197.
   PubMed Web of Science ®Google Scholar
• PELLATT J, SWEETENHAM J, PICKERING RM, BROWN L, WILKINS B: A single-centre study of treatment outcomes and survival in 120 patients with peripheral T-cell non-Hodgkin's lymphoma. Ann. Hematol (2002) 81:267–272.
   PubMedGoogle Scholar
• MORI T, KIYOKAWA N, SHIMADA H, MIYAUCHI J, FUJIMOTO J: Anaplastic large cell lymphoma in Japanese children: retrospective analysis of 34 patients diagnosed at the National Research Institute for Child Health and Development. Br. J. Haematol (2003) 121:94–96.
   PubMed Web of Science ®Google Scholar
• O'DWYER ME, MAURO MJ, DRUKER BJ: STI571 as a targeted therapy for CML. Cancer Invest. (2003) 21:429–438.
   PubMed Web of Science ®Google Scholar